William Blair & Company
ATNM icon

William Blair & Company’s Actinium Pharmaceuticals ATNM Stock Holding History

William Blair & Company’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-89,400
Closed -$952K – 1810
2022
Q4 		$952K Sell
89,400
-14,566
-14% -$148K ﹤0.01% 834
2022
Q3 		$767K Buy
103,966
+6,000
+6% +$37.3K ﹤0.01% 904
2022
Q2 		$471K Sell
97,966
-2,600
-3% -$14.8K ﹤0.01% 1086
2022
Q1 		$514K Buy
100,566
+13,700
+16% +$72.1K ﹤0.01% 1151
2021
Q4 		$522K Buy
86,866
+4,500
+5% +$33.8K ﹤0.01% 1198
2021
Q3 		$730K Buy
82,366
+30,900
+60% +$215K ﹤0.01% 1035
2021
Q2 		$407K Buy
51,466
+16,700
+48% +$131K ﹤0.01% 1226
2021
Q1 		$265K Buy
+34,766
New +$295K ﹤0.01% 1378
2019
Q2 		– Sell
-567
Closed -$8K – 1730
2019
Q1 		$8K Buy
+567
New +$9.05K ﹤0.01% 1635

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair & Company's ATNM Position: Q1 2023 in Review

William Blair & Company sold out of Actinium Pharmaceuticals (ATNM) in Q1 2023, closing a stake of 89,400 shares — an estimated $952K sold.

William Blair & Company first reported a position in ATNM in Q1 2019 and held it in 9 quarters. The position peaked at $952K in Q4 2022. 64 funds tracked by Wall St. Rank hold ATNM as of Q1 2023.

  • William Blair & Company reported no remaining Actinium Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • William Blair & Company sold 89,400 Actinium Pharmaceuticals shares in Q1 2023, an estimated $952K.
  • William Blair & Company first reported a position in Actinium Pharmaceuticals in Q1 2019 and held it in 9 quarters.
  • William Blair & Company's Actinium Pharmaceuticals position peaked at $952K in Q4 2022.
  • 64 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2023.

Based on William Blair & Company's 13F filing for Q1 2023, filed 12 May 2023.